Aromatase inhibitors in the breast cancer clinic: Focus on exemestane

Endocrine-Related Cancer

Volumn 21, Issue 1, 2014, Pages

  Van Asten, Kathleen ^a   Neven, Patrick ^a,b   Lintermans, Anneleen ^a   Wildiers, Hans ^a,b   Paridaens, Robert ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN; TEMSIROLIMUS;

BONE METABOLISM; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; COGNITION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DYSPAREUNIA; ENDOMETRIOSIS; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; LIPID METABOLISM; MONOTHERAPY; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VALVULAR HEART DISEASE;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS;

EID: 84893570176     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0269     Document Type: Review

References (180)

1. Abram P, Baum M, Berstock D, Cawthorn S, Coibion M, Fennessy M, Houghton J, Kissin M, Lee D, Mac-Rae K et al. 1996 Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Journal of the National Cancer Institute 88 1834-1839. (doi:10.1093/jnci/88.24.1834)
2. Agrawal A, Ayantunde AA, Rampaul R & Robertson JF 2007 Male breast cancer: a review of clinical management. Breast Cancer Research and Treatment 103 11-21. (doi:10.1007/s10549-006-9356-z)
3. Ahlborg HG, Johnell O, Turner CH, Rannevik G & Karlsson MK 2003 Bone loss and bone size aftermenopause. New England Journal of Medicine 349 327-334. (doi:10.1056/NEJMoa022464)
4. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR et al. 2004 The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology 15 211-217. (doi:10.1093/annonc/ mdh064)
5. Attar E & Bulun SE 2006 Aromatase and other steroidogenic genes in endometriosis: translational aspects. Human Reproduction Update 12 49-56. (doi:10.1093/humupd/dmi034)
6. Barnadas A, Gil M, González S, Tusquets I, Muñoz M, Arcusa A, Prieto L, Margelí-Vila M & Moreno A 2009 Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. British Journal of Cancer 100 442-449. (doi:10.1038/sj.bjc. 6604868)
7. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366 520-529. (doi:10.1056/NEJMoa1109653)
8. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG & Sahmoud T 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139. (doi:10.1016/S0140-6736(02)09088-8)
9. Bedaiwy MA, Mousa NA & Casper RF 2009 Aromatase inhibitors: potential reproductive implications. Journal of Minimally Invasive Gynecology 16 533-539. (doi:10.1016/j.jmig.2009.05.009)
10. Beelen K, Zwart W & Linn SC 2012 Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nature Reviews. Clinical Oncology 9 529-541. (doi:10.1038/nrclinonc.2012.121)
11. Bertelli G & Paridaens R 2006 Optimal sequence of hormonotherapy in advanced breast cancer. Current Opinion in Oncology 18 572-577. (doi:10.1097/01.cco.0000245313.97638.1d)
12. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L & Leonard RC 2005 Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69 471-477. (doi:10.1159/000090985)
13. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R et al. 2012 Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. Journal of Clinical Oncology 30 709-717. (doi:10.1200/JCO.2010.33.7899)
14. Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M, Roagna R, Serra P, Orzalesi L, Ucci G et al. 2013 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole Trial. European Journal of Cancer 49 1546-1554. (doi:10.1016/j.ejca.2012.12.025)
15. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M & von Euler M 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. Journal of Clinical Oncology 18 3748-3757.
16. Bonomo M, Mingrone W, Brauchli P, Hering F & Goldhirsch A 2003 Exemestane seems to stimulate tumour growth in men with prostate carcinoma. European Journal of Cancer 39 2111-2112. (doi:10.1016/S0959-8049(03)00486-6)
17. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, Reilly TO, Evans DB, Chen S & Lane HA 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical Cancer Research 11 5319-5328. (doi:10.1158/1078-0432.CCR-04-2402)
18. Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M & Lin Z 2005 Aromatase in endometriosis and uterine leiomyomata. Journal of Steroid Biochemistry and Molecular Biology 95 57-62. (doi:10.1016/j.jsbmb.2005.04.012)
19. Bulun SE, Chen D, Moy I, Brooks DC & Zhao H 2012 Aromatase, breast cancer and obesity: a complex interaction. Trends in Endocrinology and Metabolism 23 83-89. (doi:10.1016/j.tem.2011.10.003)
20. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP & Cameron DA 2009 A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clinical Breast Cancer 9 39-44. (doi:10.3816/CBC.2009.n.007)
21. Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P et al. 2007 Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Investigation 25 102-105. (doi:10.1080/07357900701224789)
22. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JFR et al. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. Journal of Clinical Oncology 26 1664-1670. (doi:10.1200/JCO.2007.13.5822)
23. Chin YS, Beresford MJ, Ravichandran D & Makris A 2007 Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 16 436-439. (doi:10.1016/j.breast.2007.02.002)
24. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E et al. 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncology 8 119-127. (doi:10.1016/S1470-2045(07)70003-7)
25. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC & Kilburn LS 2010 Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Research and Treatment 124 153-161. (doi:10.1007/s10549-010-1121-7)
26. Colleoni M 2011 The SOLE trial: International Breast Cancer Study Group (IBCSG 35-07) and Breast International Group (BIG 1-07) study of letrozole extension. Cancer Research 71 (Suppl 3) OT2-02-01. (doi:10.1158/0008-5472. SABCS11-OT2-02-01)
27. Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I et al. 2011 Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. Journal of Clinical Oncology 29 1117-1124. (doi:10.1200/JCO.2010.31.6455)
28. Collins B, Mackenzie J, Stewart A, Bielajew C & Verma S 2009 Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-oncology 18 811-821. (doi:10.1002/pon.1453)
29. Coombes RC, Hall E, Gibson LJ, Phil M, Paridaens RJ, Jassem J, Delozier T, Jones SE, Alvare I, Bertelli G et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 1081-1092. (doi:10.1056/NEJMoa040331)
30. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarez I et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 559-570. (doi:10.1016/S0140-6736(07)60200-1)
31. Cope S, Ouwens MJ, Jansen JP & Schmid P 2013 Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as secondline treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value in Health 16 403-417. (doi:10.1016/j.jval. 2012.10.019)
32. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A & Hershman DL 2007 Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of Clinical Oncology 25 3877-3883. (doi:10.1200/JCO.2007.10.7573)
33. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A & Powles T 2002 First results from the International Breast Cancer Intervention Study (IBIS-i): a randomised prevention trial. Lancet 360 817-824. (doi:10.1016/S0140-6736(02)09962-2)
34. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC et al. 2011 Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 771-784. (doi:10.1016/S0140- 6736(11)60993-8)
35. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X et al. 2013 Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381 805-816. (doi:10.1016/S0140-6736(12)61963-1)
36. DeCensi A, Dunn BK, Puntoni M, Gennari A & Ford LG 2012 Exemestane for breast cancer prevention: a critical shift? Cancer Discovery 2 25-40. (doi:10.1158/2159-8290.CD-11-0248)
37. De Vos FY, van Laarhoven HW, Laven JS, Themmen AP, Beex LV, Sweep CG, Seynaeve C & Jager A 2012 Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Critical Reviews in Oncology/Hematology 84 252-260. (doi:10.1016/j.critrevonc.2012.06.005)
38. Dhillon S 2013 Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73 475-485. (doi:10.1007/s40265- 013-0034-2)
39. Diorio C, Lemieux J, Provencher L, Hogue J-C & Vachon E 2012 Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Research and Treatment 136 573-579. (doi:10.1007/s10549-012-2278-z)
40. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP & Dowsett M 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Journal of Clinical Oncology 26 1671-1676. (doi:10.1200/JCO.2007.13.9279)
41. Doyen J, Italiano A, Largillier R, Ferrero J-M, Fontana X & Thyss A 2010 Aromatase inhibition in male breast cancer patients: biological and clinical implications. Annals of Oncology 21 1243-1245. (doi:10.1093/annonc/ mdp450)
42. Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F et al. 2012 Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology 30 722-728. (doi:10.1200/JCO.2011.36.8993)
43. Dunn BK, Cazzaniga M & Decensi A 2013 Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer. Breast 22 1-13. (doi:10.1016/j.breast.2013.02.015)
44. Dutta U & Pant K 2008 Aromatase inhibitors: past, present and future in breast cancer therapy. Medical Oncology 25 113-124. (doi:10.1007/s12032-007- 9019-x)
45. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW & Clack G 2008 Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. Journal of Clinical Oncology 26 1051-1057. (doi:10.1200/JCO. 2007.11.0726)
46. Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW & Coleman RE 2011 Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Annals of Oncology 22 857-862. (doi:10.1093/annonc/mdq541)
47. Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M & Costa S-D 2013 Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Research and Treatment 137 465-470. (doi:10.1007/s10549-012-2355-3)
48. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC et al. 2011 Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. Journal of Clinical Oncology 29 2342-2349. (doi:10.1200/JCO.2010. 31.6950)
49. Evans TRJ, Salle E, Di Ornati G, Lassus M, Benedetti MS, Pianezzola E & Coombes RC 1992 Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Research 52 5933-5939.
50. Ewer MS & Glück S 2009 A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 115 1813-1826. (doi:10.1002/cncr.24219)
51. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC & Hall E 2006 Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology 24 910-917. (doi:10.1200/JCO.2005.03.3654)
52. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A & Cinieri S 2012 Targeted agents to reverse resistance to endocrine therapy inmetastatic breast cancer: where are we now and where are we going? Critical Reviews in Oncology/Hematology 84 243-251. (doi:10.1016/j.critrevonc.2012.03. 004)
53. Fentiman IS, Fourquet A & Hortobagyi GN 2006 Male breast cancer. Lancet 367 595-604. (doi:10.1016/S0140-6736(06)68226-3)
54. Fisher B, Costantino JP, Wickerham LD, Redmond CK, Kavanah M, Cronin WM, Vogel VG & Wickerham DL 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 1371-1388. (doi:10.1093/jnci/90.18. 1371)
55. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS & Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53. (doi:10.1016/S1470-2045(07)70385-6)
56. Fornander T, Cedermark RN, Mattsson A, Skoog L, Glas U, Silfversw C, Somell A, Wilking N & Hjalmar M 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 117-119. (doi:10.1016/S0140-6736(89)91141-0)
57. Gaillard S & Stearns V 2011 Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Research 13 1-11. (doi:10.1186/bcr2818)
58. Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J et al. 2010 A polymorphism at the 30-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 10 1-11. (doi:10.1186/1471-2407-10-36)
59. Gasbarri A, Pompili A, Arnone B, Cavicchio A, Patrono E, Amico D, Tavares MC & Tomaz C 2011 Sex steroid hormone estrogen and cognition. Neurobiologia 74 121-138.
60. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE & Dowsett M 1998 In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clinical Cancer Research 4 2089-2093. (doi:10.1016/0959-8049(95)00623-0)
61. Geisler J, Haynes B, Anker G, Dowsett M & Lønning PE 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology 20 751-757. (doi:10.1200/JCO.20.3.751)
62. Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D & Tsavaris N 2006 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 92 13-17.
63. Giordano SH & Hortobagyi GN 2006 Leuprolide acetate plus aromatase inhibition for male breast cancer. Journal of Clinical Oncology 24 e42-e43. (doi:10.1200/JCO.2006.07.2397)
64. Glück S 2009 Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. American Journal of Clinical Oncology 33 314-319. (doi:10.1097/COC.0b013e31819fdf9b)
65. Glück S, von Minckwitz G & Untch M 2013 Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. Breast 22 142-149. (doi:10.1016/j.breast.2012.12.015)
66. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M et al. 2007 Zoledronic acid prevents cancer treatmentinduced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal cancer Study Group. Journal of Clinical Oncology 25 820-828. (doi:10.1200/JCO.2005.02.7102)
67. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine 360 679-691. (doi:10.1056/NEJMoa0806285)
68. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G et al. 2011 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 12 631-641. (doi:10.1016/S1470-2045(11)70122-X)
69. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G & Nuti R 2007 Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40 205-210. (doi:10.1016/j.bone.2006.06.027)
70. Goodwin PJ & Pritchard KI 2010 Obesity and hormone therapy in breast cancer: an unfinished puzzle. Journal of Clinical Oncology 28 3405-3407. (doi:10.1200/JCO.2010.29.5113)
71. Gorodeski GI 2002 Update on cardiovascular disease in post-menopausal women. Best Practice & Research. Clinical Obstetrics & Gynaecology 16 329-355. (doi:10.1053/beog.2002.0282)
72. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97 1262-1271. (doi:10.1093/jnci/dji250)
73. Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, Mctiernan A, Robbins J, Johnson KC, Martin LW et al. 2011 Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 364 2381-2391. (doi:10.1056/NEJMoa1103507)
74. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R et al. 2013 Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. Journal of Clinical Oncology 31 1398-1404. (doi:10.1200/JCO.2012.44.7805)
75. Gray R, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA et al. 2013 aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer. Journal of Clinical Oncology 31 Abstr 5. (doi:10.1200/JCO.2012. 47.5301)
76. Hadji P, Body J-J, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A & Tubiana-Hulin M 2008 Practical guidance for the management of aromatase inhibitor-associated bone loss. Annals of Oncology 19 1407-1416. (doi:10.1093/annonc/mdn164)
77. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L et al. 2012 Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33 1319-1326. (doi:10.1093/carcin/bgs187)
78. Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lønning PE & Dowsett M 2010 Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research 16 1790-1801. (doi:10.1158/1078-0432. CCR-09-2481)
79. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al. 2008 Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Research and Treatment 111 365-372. (doi:10.1007/s10549-007-9774-6)
80. Henry NL, Jacobson JA, Banerjee M, Hayden J, Smerage JB, Van Poznak C, Storniolo AM, Stearns V & Hayes DF 2010 A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116 4360-4367. (doi:10.1002/cncr.25385)
81. Hojo T, Kinoshita T, Imoto S, Shimizu C, Isaka H, Ito H, Imi K, Wada N, Ando M & Fujiwara Y 2013 Use of the neo-adjuvant exemestane in postmenopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. Breast 22 263-267. (doi:10.1016/j.breast.2013.03.002)
82. Howell PA, Cuzick J, Baum M, Buzdar A, Anderson M, Dowsett M, Forbes JD, Hoctin-Boes G, Houghton J, Locker GY et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62. (doi:10.1016/S0140-6736(05)74803- 0)
83. Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G et al. 2005 Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. British Journal of Cancer 92 1621-1625. (doi:10.1038/sj.bjc.6602579)
84. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 455-462. (doi:10.1016/S0140-6736(05)67059-6)
85. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
86. Jenkins V, Shilling V, Fallowfield L, Howell A & Hutton S 2004 Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study Psycho-oncology 13 61-66. (doi:10.1002/pon.709)
87. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A & Fallowfield LJ 2008 Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncology 9 953-961. (doi:10.1016/S1470-2045(08)70207-9)
88. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S & Lonning PE 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research 3 1101-1108.
89. Jones SE, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum JL, Brooks R, Hartung NL, Negron AG, Richards DA et al. 2007 Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy. Journal of Clinical Oncology 25 4765-4771. (doi:10.1200/JCO.2007.10.8274)
90. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn J, Nasurdi C, Mennel RG, Cervek J et al. 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. Journal of Clinical Oncology 18 1399-1411.
91. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I & von Minckwitz G 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. Journal of Clinical Oncology 25 2664-2670. (doi:10.1200/JCO.2006.08.8054)
92. Keen JC & Davidson NE 2003 The biology of breast carcinoma. Cancer 97 825-833. (doi:10.1002/cncr.11126)
93. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR & Fabian CJ 2010 Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment 119 111-118. (doi:10.1007/s10549-009-0495-x)
94. Kim SH, Park IH, Lee H, Lee KS, Nam B-H & Ro J 2012 Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients. Asian Pacific Journal of Cancer Prevention 13 979-983. (doi:10.7314/APJCP.2012.13.3.979)
95. Kittaneh M & Glück S 2011 Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer: Basic and Clinical Research 5 209-226. (doi:10.4137/BCBCR.S6234)
96. Lea OA, Kvinnsland S, Thorsen T & Stener K 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Research 49 7162-7167.
97. Lintermans A & Neven P 2011 Pharmacology of arthralgia with estrogen deprivation. Steroids 76 781-785. (doi:10.1016/j.steroids.2011.02.034)
98. Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS et al. 2011 Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Annals of Oncology 22 1763-1769. (doi:10.1093/annonc/mdq699)
99. Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R et al. 2013 Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Annals of Oncology 24 350-355. (doi:10.1093/annonc/mds290)
100. Litton JK, Bevers TB & Arun BK 2012 Exemestane in the prevention setting. Therapeutic Advances in Medical Oncology 4 107-112. (doi:10.1177/1758834012438214)
101. Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J et al. 2012 Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial. Cancer 118 241-247. (doi:10.1002/cncr.26299)
102. Lombardi P 2002 Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochimica et Biophysica Acta 1587 326-337. (doi:10.1016/S0925-4439(02)00096-0)
103. Lønning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189. (doi:10.1677/erc.0.0110179)
104. Lønning PE 2009 Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer 45 527-535. (doi:10.1016/j.ejca.2008.10.019)
105. Lønning PE & Eikesdal HP 2013 Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer 20 R183-R201. (doi:10.1530/ERC-13-0099)
106. Lønning PE & Geisler J 2010 Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology 118 288-293. (doi:10.1016/j.jsbmb.2009.09.013)
107. Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK et al. 2000 Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 18 2234-2244.
108. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J et al. 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Journal of Clinical Oncology 23 5126-5137. (doi:10.1200/JCO.2005.07.097)
109. Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S & Dowsett M 2011 Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clinical Cancer Research 17 4948-4958. (doi:10.1158/1078-0432.CCR-11-0043)
110. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V et al. 2009 Breast cancer metastasis: challenges and opportunities. Cancer Research 69 4951-4953. (doi:10.1158/0008-5472.CAN-09-0099)
111. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y & Brodie A 2006 Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Research 66 7775-7782. (doi:10.1158/0008-5472.CAN-05-3984)
112. Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN et al. 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical Adjuvant Breast and Bowel Project B-33 trial. Journal of Clinical Oncology 26 1965-1971. (doi:10.1200/JCO.2007.14.0228)
113. Mao J, Stricker C, Bruner D, Xie S, Bowman M, Farrar J, Greene B & DeMichele A 2009 Patterns and risk factors associated with aromatase inhibitor related arthralgia among breast cancer survivors. Cancer 115 3631-3639. (doi:10.1002/cncr.24419)
114. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J,
115. Markopoulos C, Dafni U, Misitzis J, Zobolas V, Tzoracoleftherakis E, Koukouras D, Xepapadakis G, Papadiamantis J, Venizelos B, Antonopoulou Z et al. 2009a Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research 11 1-9. (doi:10.1186/bcr2320)
116. Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G & Gogas H 2009b Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of Oncology 20 49-55. (doi:10.1093/annonc/mdn545)
117. Mauri D, Pavlidis N, Polyzos NP & Ioannidis JPA 2006 Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute 98 1285-1291. (doi:10.1093/jnci/djj357)
118. Mauriac L, Romieu G & Bines J 2009 Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Research and Treatment 117 69-75. (doi:10.1007/s10549-008-0141-z)
119. Mayordomo J, Llombart A, Martin M, Antón A, Barnadas A, Antolin S, Alés-Martinez J & Alvarez I 2006 Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. Journal of Clinical Oncology 24 (Suppl 18S) 638.
120. Meier CR & Jick H 1998 Tamoxifen and risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology 45 608-612. (doi:10.1046/j.1365-2125.1998.00733.x)
121. Mieog JS, Morden JP, Bliss JM, Coombes RC & van de Velde CJ 2012 Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncology 13 420-432. (doi:10.1016/S1470-2045(11)70328-X)
122. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H et al. 2008 Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13 829-837. (doi:10.1634/theoncologist.2008-0055)
123. Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I et al. 2005 Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Annals of Oncology 16 70-74. (doi:10.1093/annonc/mdi021)
124. Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P et al. 2007 Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Research and Treatment 104 87-91. (doi:10.1007/s10549-006-9394-6)
125. Mortimer JE 2010 Managing the toxicities of the aromatase inhibitors. Current Opinion in Obstetrics & Gynecology 22 56-60. (doi:10.1097/GCO. 0b013e328334e44e)
126. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F et al. 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. Journal of Clinical Oncology 21 2101-2109. (doi:10.1200/JCO.2003.04.194)
127. Mousa NA, Bedaiwy MA & Casper RF 2007 Aromatase inhibitors in the treatment of severe endometriosis. Obstetrics and Gynecology 109 1421-1423. (doi:10.1097/01.AOG.0000265807.19397.6d)
128. Nabholtz J-M 2008 Long-term safety of aromatase inhibitors in the treatment of breast cancer. Therapeutics and Clinical Risk Management 4 189-204. (doi:10.2147/TCRM.S1566)
129. Nabholtz J-M, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology 18 3758-3767.
130. Nadji M, Gomez-Fernandez C, Ganjei-Azar P & Morales AR 2005 Immunohistochemistry of estrogen and progesterone receptors reconsidered. American Journal of Clinical Pathology 123 21-27. (doi:10.1309/4WV79N2GHJ3X1841)
131. Neven P, De Muylder X, Van Belle Y, Vanderick G & De Muylder E 1989 Tamoxifen and the uterus and endometrium. Lancet 1 375. (doi:10.1016/S0140- 6736(89)91741-8)
132. Nordman IC, Spillane AJ & Hamilton AL 2005 The aromatase inhibitors in early breast cancer: who, when, and why? Medical Journal of Australia 183 24-27.
133. Ortmann O, Cufer T, Dixon JM, Maass N, Marchetti P, Pagani O, Pronzato P, Semiglazov V, Spano J-P, Vrdoljak E et al. 2009 Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 18 2-7. (doi:10.1016/j.breast.2008.10.002)
134. Paganini-Hill A & Clark LJ 2000 Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment 64 165-176. (doi:10.1023/A:1006426132338)
135. Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S et al. 1998 Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anti-Cancer Drugs 9 675-683. (doi:10.1097/00001813- 199809000-00002)
136. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J & Therasse P 2008 Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology 26 4883-4890. (doi:10.1200/JCO.2007.14.4659)
137. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS & Goldhirsch A 2010 Adjuvant! online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor- positive breast cancer. Breast Cancer Research and Treatment 123 303-310. (doi:10.1007/s10549-010-0794-2)
138. Pauwels S, Antonio L, Jans I, Lintermans A, Neven P, Claessens F, Decallonne B, Billen J, Vanderschueren D & Vermeersch P 2013 Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization. Analytical and Bioanalytical Chemistry 405 8569-8577. (doi:10.1007/s00216-013-7259-5)
139. Pavone ME & Bulun SE 2012 Aromatase inhibitors for the treatment of endometriosis. Fertility and Sterility 98 1370-1379. (doi:10.1016/j.fertnstert. 2012.08.053)
140. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE et al. 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Journal of Clinical Oncology 24 3629-3635. (doi:10.1200/JCO.2005.05.4882)
141. Peterson ME 2013 Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive Care in Cancer 21 2341-2349. (doi:10.1007/s00520-013-1826-3)
142. Phillips KA, Ribi K & Fisher R 2011a Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Research 13 1-7. (doi:10.1186/bcr2806)
143. Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS et al. 2011b Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Research and Treatment 126 221-226. (doi:10.1007/s10549- 010-1235-y)
144. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C & Mauri D 2009 Aromatase inhibitors for female infertility: a systematic review of the literature. Reproductive Biomedicine Online 19 456-471. (doi:10.1016/j.rbmo. 2009.06.008)
145. Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C & Howard F 2007 Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in nonclinical trial patients. Clinical Breast Cancer 7 775-778. (doi:10.3816/CBC.2007.n.038)
146. Rao BR & Cobleigh MA 2012 Adjuvant endocrine therapy for breast cancer. Oncology 26 1-12.
147. Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N & Ellis MJ 2011 Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Research and Treatment 129 107-116. (doi:10.1007/s10549-011-1644-6)
148. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN & Donohue JH 1998 Molecular markers in male breast carcinoma. Cancer 83 1947-1955. (doi:10.1002/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J)
149. Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA & James VH 1989 In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. International Journal of Cancer 44 233-237. (doi:10.1002/ijc.2910440208)
150. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B & Gelber RD 2011 Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research 13 209. (doi:10.1186/bcr2837)
151. Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW & Kleijnen J 2010 Systematic review of aromatase inhibitors in the firstline treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Research and Treatment 123 9-24. (doi:10.1007/s10549-010-0974-0)
152. Rutqvist LE & Johansson H 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncologica 46 133-145. (doi:10.1080/02841860601034834)
153. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS et al. 2010 Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology 28 1294-1300. (doi:10.1200/JCO.2008.21.3553)
154. Shanafelt TD, Barton DL, Adjei AA & Loprinzi CL 2002 Pathophysiology and treatment of hot flashes. Mayo Clinic Proceedings 77 1207-1218. (doi:10.4065/77.11.1207)
155. Sherwin BB 2012 Estrogen and cognitive functioning in women: lessons we have learned. Behavioral Neuroscience 126 123-127. (doi:10.1037/a0025539)
156. Simpson E 2003 Sources of estrogen and their importance. Journal of Steroid Biochemistry and Molecular Biology 86 225-230. (doi:10.1016/S0960- 0760(03)00360-1)
157. Smith IE & Dowsett M 2003 Aromatase inhibitors in breast cancer. New England Journal of Medicine 348 2431-2442. (doi:10.1056/NEJMra023246)
158. Smith IE, Dowsett M, Yap Y-S, Walsh G, Lønning PE, Santen RJ & Hayes D 2006 Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of Clinical Oncology 24 2444-2447. (doi:10.1200/JCO.2005.05.3694)
159. Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O & Cameron D 2006 Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 15 430-436. (doi:10.1016/j.breast.2005.08.032)
160. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E & Naughton MJ 2010 Incidence and time course of bleeding after long-termamenorrhea after breast cancer treatment: a prospective study. Cancer 116 3102-3111. (doi:10.1002/cncr.25106)
161. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. International Journal of Cancer 120 285-291. (doi:10.1002/ijc.22317)
162. Swedish Breast Cancer Cooperative Group 1996 Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute 88 1543-1549. (doi:10.1093/jnci/88.21.1543)
163. Thomas R, Williams M, Marshall C & Walker L 2008 Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. British Journal of Cancer 98 1494-1499. (doi:10.1038/sj.bjc.6604323)
164. Thürlimann B, Paridaens R, Serin D, Bonneterre J, Rochc H, Murray R, Salle E, Lanzalone S, Zurlo MG & Piscitelli G 1997 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. European Journal of Cancer 33 1767-1773. (doi:10.1016/S0959-8049(97)00283-9)
165. Thürlimann B, Keshavia A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Vastiglione-Gertsch M, Gelber RD, Rabaglio M et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 2747-2757. (doi:10.1056/ NEJMoa052258)
166. van de Velde CJ, Verma S, van Nes JG, Masterman C & Pritchard KI 2010 Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treatment Reviews 36 54-62. (doi:10.1016/j.ctrv.2009.10.003)
167. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM et al. 2011 Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377 321-331. (doi:10.1016/S0140-6736(10)62312-4)
168. Vermeulen A, Deslypere JP & Paridaens R 1986 Steroid dynamics carcinomatous in the normal and mammary gland. Journal of Steroid Biochemistry 25 799-802. (doi:10.1016/0022-4731(86)90311-0)
169. Walker G, Xenophontos M, Chen L & Cheung K 2013 Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Preference and Adherence 7 245-258. (doi:10.2147/PPA.S42223)
170. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ et al. 2010 Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Research 70 319-328. (doi:10.1158/0008-5472.CAN-09-3224)
171. Waters EA, Cronin KA, Graubard BI, Han PK & Freedman AN 2010 Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiology, Biomarkers & Prevention 19 443-446. (doi:10.1158/1055-9965.EPI-09-0930)
172. Wiggins DL & Dizon DS 2008 Dyspareunia and vaginal dryness after breast cancer treatment. SRM Sexuality, Reproduction & Menopause Breast Cancer 6 18-22.
173. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al. 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology 23 619-629. (doi:10.1200/JCO.2005.09.121)
174. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P et al. 2013 Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology 31 195-202. (doi:10.1200/JCO.2011. 38.3331)
175. Young LH, The How & Grows H 2000 Special situations. Heart disease in the elderly. In Yale University School of Medicine Heart Book, edn 1, pp 263-271. Eds BL Zaret, M Moser, LS Cohen & GJ Subak-Sharpe., New York: William Morrow and Company, Inc.
176. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos M et al. 2013 Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. British Journal of Cancer 108 2259-2263. (doi:10.1038/bjc.2013.255)
177. Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C et al. 2012 Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology 23 1474-1481. (doi:10.1093/annonc/mdr448)
178. Zhang Y, Simondsen K & Kolesar JM 2012 Exemestane for primary prevention of breast cancer in postmenopausal women. American Journal of Health-System Pharmacy 69 1384-1388. (doi:10.2146/ajhp110585)
179. Zickl L, Francis P, Fleming G, Pagani O, Walley B, Price K, Gelber R, Regan M, Group International Breast Cancer Study & Cancer Group North American Breast 2012 SOFT and TEXT: trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer. thirty-fifth annual antonio breast cancer symposium. Cancer Research 72 (Suppl 3) 568s-569s. (doi:10.1158/0008-5472. SABCS12-OT2-2-01)
180. Zilembo N, Bajetta E, Bichisao E, Martinetti A, La Torre I, Bidoli P, Longarini R, Portale T, Seregni E & Bombardieri E 2004 The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Biomedicine & Pharmacotherapy 58 255-259. (doi:10.1016/j.biopha. 2003.12.009)